Results 41 to 50 of about 1,454 (181)
, 2023 Supplemental material, sj-jpg-1-cep-10.1177_03331024231152169 for Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Roberta Messina, Eva-Maria ...
Eva-Maria Huessler (14617393) +5 more
core +1 more source
, 2023 Supplemental material, sj-jpg-2-cep-10.1177_03331024231152169 for Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Roberta Messina, Eva-Maria ...
Eva-Maria Huessler (14617393) +5 more
core +1 more source
, 2020 PURPOSE OF REVIEW: Migraine is the second leading cause of years lived with disability after back pain. Poor tolerability, contraindications, drug-drug interactions and efficacy limited to a subpopulation make new approaches necessary for the acute and ...
Goadsby, Peter J.; id_orcid +2 more
core +1 more source
, 2023 Supplemental material, sj-pdf-2-cep-10.1177_03331024231159366 for Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials by ...
Patricia Pozo-Rosich (4320316) +5 more
core +1 more source
, 2023 Supplemental material, sj-pdf-1-cep-10.1177_03331024231159366 for Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials by ...
Patricia Pozo-Rosich (4320316) +5 more
core +1 more source
, 2023 Supplemental material, sj-jpg-4-cep-10.1177_03331024231152169 for Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Roberta Messina, Eva-Maria ...
Eva-Maria Huessler (14617393) +5 more
core +1 more source
, 2023 Supplemental material, sj-jpg-5-cep-10.1177_03331024231152169 for Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis by Roberta Messina, Eva-Maria ...
Eva-Maria Huessler (14617393) +5 more
core +1 more source
New strategies for migraine treatment and prevention
Aktualności Neurologiczne, 2019 Migraine is a neurological disorder characterised by recurrent attacks of headache accompanied by vegetative symptoms. It is estimated that 11–12% of the world’s population suffers from migraine.
Waldemar Brola, Piotr Sobolewski
doaj +1 more source
Advances in Acute Migraine Therapy: Triptans Compared with CGRP Receptor Antagonists
Journal of Education, Health and SportIntroduction and purpose: Migraine is one of the most common and disabling neurological disorders. Attacks significantly decrease quality of life and daily functioning; therefore, effective treatment is crucial.
Michał Chodor +2 more
doaj +1 more source
Preventive and abortive treatment of migraine with traditional drugs - the state of the art
Headache Medicine, 2023 Introduction Migraine is a chronic neurological disease, with a prevalence of 15.2% in Brazil. It is 2.2 times more prevalent in women, predominantly in the 18-50 age group. Its pathophysiological mechanism is still not completely understood.
Raimundo Pereira Silva-Néto +2 more
doaj +1 more source